Literature DB >> 1855204

Studies on the interaction between interleukin 6 and human malignant nonhematopoietic cell lines.

H Serve1, G Steinhauser, D Oberberg, W A Flegel, H Northoff, W E Berdel.   

Abstract

We have previously reported on stimulation of clonal growth of cell lines from human solid tumors by recombinant human interleukin 3, recombinant human granulocyte-macrophage colony-stimulating factor, and recombinant human granulocyte colony-stimulating factor (W. E. Berdel et al., Blood, 73: 80-83, 1989; Exp. Hematol., 16: 510, 1988). Within an extensive screening program of hematopoietic growth factor activity on malignant cells, the effects of recombinant human interleukin 6 (rhIL-6) were tested on the growth (tritiated thymidine uptake and human tumor cloning assay) of 26 different human cell lines derived from a wide range of solid tumors (head and neck, 4; lung, 1; pancreatic, 1; gastric, 1; colorectal, 3; renal, 3; bladder, 1; prostate, 1; breast, 2; ovary, 2; choriocarcinoma, 1; sarcoma, 2; glioblastoma, 2; neuroblastoma, 2). rhIL-6 (dose range up to 10(4) IU/ml) caused no reproducible enhancement or inhibition of tritiated thymidine uptake by tumor cell lines from nonhematopoietic origin. Furthermore, 19 of the tumor cell lines were clonogenic in a capillary modification of the human tumor cloning assay. No reproducible stimulation of clonal growth by rhIL-6 was observed in any of the cells tested. Particularly, there was no sensitivity of those cell lines for rhIL-6, which were previously shown to be sensitive for recombinant human interleukin 3 and recombinant human granulocyte-macrophage colony-stimulating factor in this assay. On the other hand, there were no significant growth-inhibitory effects of rhIL-6 on the cell lines tested in this study. Further experiments showed no influence of neutralizing monoclonal anti-hIL-6 antibody on the growth of 3 kidney carcinoma cell lines, making autocrine growth-modulating loops for IL-6 in these lines unlikely. In conclusion, no major interactions between hIL-6 and the growth of the human malignant cell lines from nonhematopoietic origin tested were detected in this study.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1855204

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  7 in total

1.  Mesothelin overexpression promotes autocrine IL-6/sIL-6R trans-signaling to stimulate pancreatic cancer cell proliferation.

Authors:  Uddalak Bharadwaj; Christian Marin-Muller; Min Li; Changyi Chen; Qizhi Yao
Journal:  Carcinogenesis       Date:  2011-04-23       Impact factor: 4.944

2.  Expression of the interleukin 6 receptor in primary renal cell carcinoma.

Authors:  V Costes; J Liautard; M C Picot; M Robert; N Lequeux; J Brochier; P Baldet; J F Rossi
Journal:  J Clin Pathol       Date:  1997-10       Impact factor: 3.411

3.  Interleukin 6: a fibroblast-derived growth inhibitor of human melanoma cells from early but not advanced stages of tumor progression.

Authors:  C Lu; M F Vickers; R S Kerbel
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-01       Impact factor: 11.205

4.  Interleukin-6 enhances hypercalcemia and bone resorption mediated by parathyroid hormone-related protein in vivo.

Authors:  J de la Mata; H L Uy; T A Guise; B Story; B F Boyce; G R Mundy; G D Roodman
Journal:  J Clin Invest       Date:  1995-06       Impact factor: 14.808

Review 5.  Expression of multi-cytokine resistance and multi-growth factor independence in advanced stage metastatic cancer. Malignant melanoma as a paradigm.

Authors:  R S Kerbel
Journal:  Am J Pathol       Date:  1992-09       Impact factor: 4.307

6.  Constitutive production of multiple cytokines and a human chorionic gonadotrophin beta-subunit by a human bladder cancer cell line (KU-19-19): possible demonstration of totipotential differentiation.

Authors:  M Tachibana; A Miyakawa; J Nakashima; M Murai; K Nakamura; A Kubo; J I Hata
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

7.  Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression.

Authors:  C Lu; R S Kerbel
Journal:  J Cell Biol       Date:  1993-03       Impact factor: 10.539

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.